
CAS 1562993-37-6
:Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
3 Produkte.
Ponatinib-d8
CAS:Ponatinib D8 is a deuterium-enriched, oral multi-kinase inhibitor (Abl, PDGFRα, VEGFR2, FGFR1, Src; IC50s: 0.37-5.4 nM).Formel:C29H27F3N6OReinheit:98%Farbe und Form:SolidMolekulargewicht:540.61Ponatinib-d8
CAS:Kontrolliertes Produkt<p>Applications Ponatinib-d8 is an isotope labelled compound of Ponatinib (P688250). Ponatinib is a tyrosine kinase inhibitors (TKI) and used to treat chronic myeloid leukemia (CML) (1,2,3). Ponatinib is also used in combination with other drugs, such as forskolin, to combat TKI resistance in patient with CML (3), targeted drug in small-cell lung cancer. It is a COVID19-related research product.<br>References Skora, L., et al.: ACS Med. Chem. Lett., PagesAhead of Print (2017); Uchibori, K., et al.: Nat. Commun., 8, 14768 (2017); Perrotti, D., et al.: Curr. Drug Targets, 18, 377 (2017); Santarpia, M., et al.: Trans. Lung Cancer Res., 5, 51 (2016); Halbach, S., et al.: Cell Commun. Signal., 14, 6 (2016)<br></p>Formel:C29H19D8F3N6OFarbe und Form:NeatMolekulargewicht:540.61


